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Abstract 
Objective: Soluble CD40 ligand (sCD40L) is reported to be associated with a disruption of the 
blood–brain barrier (BBB). We aimed to elucidate the role of sCD40L on multiple sclerosis (MS) 
and neuromyelitis optica spectrum disorder (NMOSD).  
Methods: CSF and serum sCD40L levels were measured in 29 MS, 29 NMOSD, and 27 disease 
control (DC) patients. Clinical and laboratory profiles including the CSF/serum albumin ratio 
(Qalb), a marker of BBB breakdown, and interleukin-6 (IL-6) levels were also investigated.  
Results: In MS patients, serum sCD40L levels were higher than in DCs (median: 2480 versus 
786 pg/mL, P = 0.046) and positively correlated with Qalb (P = 0.044). CSF sCD40L levels in 
MS patients were elevated compared to DCs (median: 38.5 vs 4.8 pg/mL, P = 0.002) but were 
not correlated with Qalb (P = 0.72). In contrast, in NMOSD patients serum sCD40L levels were 
not elevated compared to DCs (median: 829 vs 786 pg/mL, P = 0.87) and showed no correlation 
with Qalb (P = 0.89). But, CSF sCD40L levels were significantly increased compared to DCs 
(median: 33.5 vs 4.8 pg/mL, P = 0.013), tended to be related with Qalb (P = 0.056), and were 
correlated to CSF cell counts, protein concentrations, and IL-6 levels (P =0.038, 0.018, and 0.015, 
respectively).  
Conclusions: sCD40L could be involved in BBB disruption in MS, whereas it may contribute to 
CNS inflammation in NMOSD. 
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Introduction 
CD40 ligand (CD40L) is a transmembrane protein that plays an important role in the immune 
system, helping to produce high-affinity B cells and to promote neutrophil adhesion and 
migration via the integrin Mac-1.
1,2
 Soluble CD40L (sCD40L), which has the same function as 
CD40L,
3
 was reported to be produced by shedding from the surface of activated platelets or 
activated T cells and exist in trimers.
1
 Recent studies have suggested that sCD40L increases the 
permeability of the blood–brain barrier (BBB).4  
Helper T (Th) 17 cells were reported to play an important role in the pathogenesis of MS.
5–10
 
A recent study showed blocking interleukin-6 (IL-6) receptor signaling in vitro decreased the 
monocyte ability to up-regulate Th17 cells in multiple sclerosis (MS) patients.
11
 Conversely, IL-6 
was also known to be a key molecule in the pathogenesis of neuromyelitis optica spectrum 
disorder (NMOSD).
12–15
  
Previous studies revealed that sCD40L was increased in the sera of patients with 
autoimmune diseases including systemic lupus erythematosus (SLE)
16,17
 and primary Sjögren 
syndrome.
18
 Moreover, increased sCD40L levels were reported in the CSF of MS patients and in 
the sera of NMOSD patients.
19,20
 However, the role of sCD40L in MS and NMOSD have not 
been identified. Therefore, we examined serum and CSF sCD40L levels in MS and NMOSD 
patients and investigated the correlation of sCD40L with clinical characteristics or laboratory and 
IL-6 profiles.  
 
Materials and methods 
Patients 
We included 29 MS patients, 29 NMOSD patients, and 27 disease control (DC) patients. All MS 
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patients fulfilled the 2010 revisions of the McDonald criteria
21
 and all patients with NMOSD 
implemented the 2015 international consensus diagnostic criteria,
22
 including 19 patients with 
neuromyelitis optica (NMO).
23
 DC patients were as follows; 10 with inflammatory diseases (two 
CNS lupus, four neurosarcoidosis, and four Behçet disease [one Entero-Behçet disease and three 
Neuro-Behçet disease]) and 17 with non-inflammatory diseases (one corticobasal syndrome, six 
motor neuron disease, three multiple system atrophy, five Parkinson’s disease, one progressive 
supranuclear palsy, and one spinocerebellar degeneration). 
 
Standard Protocol Approvals and Patient Consents 
The study procedure was approved by the ethics committee of Chiba University School of 
Medicine. All patients provided informed consent. 
 
Collecting CSF and serum samples 
All samples from MS and NMOSD patients were obtained during an attack, the same as a 
previous report,
24
 that is, all samples were obtained within 50 d after the onset of an attack and 
before treatment. Samples from DC patients with inflammatory diseases were obtained during the 
acute phase. Serum samples were collected simultaneously at CSF sampling. All serum samples 
were centrifuged at 3000 rpm for 10 min. All serum samples just after centrifugation and all CSF 
samples were immediately stored at - 80°C until analysis. 
  
CSF and serum sCD40L measurements 
The concentration of sCD40L in the CSF and serum was analyzed using the Bio-Plex ProTM® 
magnetic bead based immunoassay (Bio-Rad Laboratories, Hercules, CA, USA) with a single 
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detection according to the manufacturer’s instructions. Fluorescence intensity from the 
immunoassay was measured and analyzed using Bio-Plex TM 200 system software version 6.1 
(Bio-Rad Laboratories). The sCD40L concentration (pg/mL) was calculated by a standard curve 
obtained by standard assays. Values under the dynamic range were replaced by half of the lower 
limit of sensitivity. 
 
Clinical characteristics and laboratory findings 
We reviewed age at disease onset, gender, disease duration to sampling, age at sampling, 
Kurtzke’s Expanded Disability Status Scale (EDSS) at sampling, and treatments at sampling. 
Laboratory findings including anti-aquaporin-4 antibodies positivity,
25
 CSF cell count, CSF 
protein concentration, CSF/serum albumin ratio (Qalb), IgG index, oligoclonal IgG bands, and 
platelet count were also reviewed. These items were compared among MS patients, NMOSD 
patients, and DCs. Correlations between sCD40L levels and other clinical or laboratory items 
were also investigated. 
 
Comparing sCD40L levels and IL-6 data of a previous report 
We previously reported CSF and serum IL-6 levels in MS and NMO patients. Hence, the 
correlation between sCD40L levels and IL-6 levels previously reported was investigated.
24
 
 
Statistical analysis 
Continuous data were compared between disease groups by a Mann-Whitney U test with a 
Bonferroni correction. Categorical outcomes were evaluated using the chi-square test or Fisher’s 
exact test. A Kendall tau-b correlation was performed to analyze correlations. A P value of <0.05 
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was considered statistically significant. Statistical tests were conducted using SPSS version 23.0 
(IBM Corporation, Armonk, NY, USA).  
 
Results 
Demographics, clinical characteristics, and laboratory findings in patients with MS, NMOSD, 
and DCs 
Demographics, clinical characteristics, and laboratory findings in patients with MS and NMOSD 
are shown in Table 1. Age at CSF sampling and EDSS were significantly lower in MS patients 
than in NMOSD patients (P < 0.001, both). Anti-aquaporin-4 antibodies were only positive in 
NMOSD patients (83%, P < 0.001). Long extended cord lesion, Qalb, and the number of patients 
with any immunomodulating treatment and continuous oral prednisolone were significantly 
higher in patients with NMOSD than in patients with MS (all P values were <0.001). Meanwhile, 
the positivity for oligoclonal IgG bands was higher in patients with MS than in patients with 
NMOSD (P = 0.027). The IgG index and platelet count were not different between MS and 
NMOSD patients. For DCs, 17 patients were female (63.0%), and the median age at CSF 
sampling was 60.0 years and the interquartile range (IQR) of age at CSF sampling was 14.0 years. 
The median and IQR of platelet counts in DCs were 233 and 93.5 ×10
3/μL, respectively. Platelet 
count was not different between DCs and MS or NMOSD. 
 
Serum and CSF sCD40L levels in patients with MS, NMOSD, and DCs 
Serum sCD40L levels in MS patients tended to be higher than DCs (median: 2480 vs 786 pg/mL, 
IQR: 2590 vs 1379, P = 0.046, Figure 1A). However, compared with DCs, the results showed 
that CSF sCD40L levels were significantly higher in patients with MS (median: 38.5 vs 4.8 
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pg/mL, IQR: 45.7 vs 23.6, P = 0.002) and NMOSD (median: 33.5 vs 4.8 pg/mL, IQR: 38.4 vs 
23.6, P = 0.013) (Figure 1B). No significant difference was found in CSF sCD40L levels 
between MS and NMOSD.  
 
Correlations between sCD40L levels and other clinical characteristics or laboratory findings in 
MS patients 
Correlations between sCD40L levels and other clinical characteristics or laboratory findings in 
patients with MS are shown in Table 2. In MS patients, serum sCD40L levels were positively 
correlated with Qalb (Kendall tau-b = 0.29, P = 0.044). In contrast, no correlation was found 
between CSF sCD40L levels and Qalb in MS patients (Kendall tau-b = - 0.054, P = 0.72). Other 
items were not correlated with serum sCD40L or CSF sCD40L levels in MS patients.  
 
Correlations between sCD40L levels and other clinical characteristics or laboratory findings in 
NMOSD patients 
Correlations between sCD40L levels and other clinical characteristics or laboratory findings in 
patients with NMOSD are shown in Table 3. In NMOSD patients, positive correlations were 
found between CSF sCD40L levels and CSF cell counts (Kendall tau-b = 0.30, P = 0.038) and 
between CSF sCD40L levels and CSF protein levels (Kendall tau-b = 0.34, P = 0.018). IgG index 
and Qalb tended to be positively correlated with CSF sCD40L levels (Kendall tau-b = 0.28, P = 
0.056, both). However, serum sCD40L levels were not correlated with Qalb in NMOSD patients 
(Kendall tau-b = 0.022, P = 0.89). No correlations were found between other items and serum or 
CSF sCD40L levels.  
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Correlation of sCD40L levels with IL-6 levels  
Correlations of sCD40L levels with IL-6 levels in MS and NMOSD patients are shown in figure 
e-1. In MS patients, serum sCD40L levels were correlated with serum IL-6 (Kendall tau-b = 0.51, 
P = 0.001) but not with CSF IL-6 (Kendall tau-b = - 0.035, P = 0.79). On the other hand, CSF 
sCD40L levels showed no correlation with either CSF IL-6 levels (Kendall tau-b = 0.058, P = 
0.68) or serum IL-6 levels (Kendall tau-b = - 0.027, P = 0.86) in MS patients. In patients with 
NMOSD, a positive correlation with CSF sCD40L levels was found in CSF IL-6 (Kendall tau-b = 
0.34, P = 0.015) but not with serum IL-6 (Kendall tau-b = 0.30, P = 0.061). Meanwhile, serum 
sCD40L levels showed no correlations with CSF IL-6 (Kendall tau-b = - 0.085, P = 0.52) or 
serum IL-6 (Kendall tau-b = 0.17, P = 0.28) levels.  
 
Discussion 
Our results suggest a somewhat different role of sCD40L in the pathophysiology of MS and 
NMOSD. In MS, both serum and CSF sCD40L levels were significantly elevated, but only serum 
sCD40L levels showed a positive correlation with Qalb, suggesting their involvement in BBB 
breakdown. By contrast, in NMOSD, sCD40L levels were significantly increased in CSF but not 
in serum, whereas the CSF sCD40L levels were correlated with CSF cell counts, CSF protein 
concentrations, and CSF IL-6 levels, indicating a more severe inflammation in the CNS. 
Some studies reported sCD40L levels were increased in the sera from patients with SLE and 
primary Sjögren syndrome.
16–18
 Serum sCD40L levels in SLE patients were reported to be 
correlated with disease severity. That is, sCD40L levels were significantly higher in patients with 
severe SLE than in patients with moderate and mild SLE.
3
 However, the function of sCD40L in 
these diseases is still unclear. 
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Meanwhile, previous reports have shown that elevated sCD40L levels could increase BBB 
permeability.
4,26
 In those reports, the authors found increased plasma and CSF sCD40L levels in 
patients with HIV-associated neurocognitive disorder (HAND). They showed BBB permeability 
in HAND was dependent on CD40L with CD40L knock out mice.
4
 Our study revealed a 
tendency for increased serum sCD40 levels and a positive correlation between serum sCD40L 
levels and Qalb in MS patients. On the other hand, in NMOSD patients, our results showed 
increased CSF sCD40L levels and a positive correlation of CSF sCD40L levels with Qalb. These 
results may indicate that sCD40L plays an important role in the destruction of the BBB in MS 
and NMOSD, and that the place where sCD40L plays a role in the destruction of the BBB may 
be different between MS and NMOSD. That is, sCD40L may affect the BBB from the peripheral 
side in MS and from the CNS side in NMOSD. 
Previous studies reported only activated platelets or activated T cells could release sCD40L. 
Few studies have investigated whether platelets could migrate into the brain, but a study showed 
that platelets did not migrate into the brain of Alzheimer disease patients but were concentrated in 
the blood vessels.
27
 Therefore, in the CNS, only T cells could produce sCD40L. In NMOSD, a 
recent study showed that not only NMO-IgG but also highly encephalitogenic T cells were 
required to cause severe panencephalitis.
28
 Activated pathogenic T cells in the CNS may release 
sCD40L, leading to a breakdown of the BBB and severe inflammation in the CNS. In addition, 
IL-6 was reported to contribute to disease severity.
29
 Therefore, elevated CSF sCD40L levels and 
a positive correlation of CSF sCD40L with CSF IL-6 levels, CSF cell count, and CSF protein 
concentration could lead to severe inflammation through a BBB breakdown in NMOSD. 
Different from NMOSD, activated platelets or activated T cells may produce sCD40L 
peripherally, leading to a breakdown of the BBB. Further investigation is needed to clarify the 
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origin of sCD40L in the pathogenesis of MS and NMOSD. 
There are some limitations in our study. First, the sample size was limited. Second, we 
measured sCD40L levels in serum but not plasma. This may have affected the results. Plasma 
sCD40L levels are usually higher than serum levels, because 95% of sCD40L is produced from 
activated platelets in plasma.
30,31
 Our assay using serum may reflect sCD40L from T 
lymphocytes, another source of sCD40L, more than assays using plasma. Second, the molecular 
weight of sCD40L is much smaller than albumin, resulting in its easier access to the CNS. 
Therefore, the possibility that the elevated CSF sCD40L levels in MS and NMOSD reflected the 
serum sCD40L levels cannot be denied. Previously, an anti-CD40L antibody caused 
thromboembolism in SLE patients.
32
 Recently, new anti-CD40L antibodies lacking a functional 
Fc region were reported not to induce thrombotic events.
33
 Our study indicates that a destruction 
of the BBB may be mediated by elevated serum sCD40L in MS and CSF sCD40L in NMOSD. 
Therefore, in the future, an anti-CD40L antibody lacking the Fc region could be a potential drug 
for patients with MS and NMOSD. 
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Figure Legends 
Figure 1. Comparison of sCD40L levels in MS, NMOSD, and DCs. 
(A) Serum sCD40L levels tended to be higher in MS patients than in DCs. No differences were 
found between MS and NMOSD, NMOSD and DCs. (B) CSF sCD40L levels were increased in 
patients with MS and NMOSD compared with DCs. In DCs, 10 inflammatory diseases (two CNS 
lupus, four sarcoidosis, three Neuro-Behçet disease, and one Behçet disease) and 17 non-
inflammatory diseases (one corticobasal syndrome, six motor neuron disease, three multi system 
atrophy, five Parkinson’s disease, one progressive supranuclear palsy, and one spinocerebellar 
degeneration) were included. In DCs, gray and white circles indicate sCD40L levels of 
inflammatory and non-inflammatory diseases, independently. Grey long-short dashed lines show 
the medians of each group. DCs = disease control; L.L.D. = lower limit of detection; MS = 
multiple sclerosis; NMOSD = neuromyelitis spectrum disorder; sCD40L = soluble CD40 ligand.  
 
Figure 2. Correlations between sCD40L levels and Qalb in MS and NMOSD. 
(A) Positive correlation between serum sCD40L levels and Qalb in MS patients. (B) No 
correlation between serum sCD40L levels and Qalb in NMOSD patients. (C) No correlation 
between CSF sCD40L levels and Qalb in MS patients. (D) Positive correlations between CSF 
sCD40L levels and Qalb in NMOSD patients. MS = multiple sclerosis; NMOSD = neuromyelitis 
spectrum disorder; Qalb = CSF/serum albumin ratio; sCD40L = soluble CD40 ligand. 
 
Figure 3. Correlations between sCD40L levels and IL-6 levels in MS and NMOSD 
(A) Positive correlation between serum sCD40L levels and serum IL-6 levels in MS patients. (B) 
No correlation between serum sCD40L levels and serum IL-6 levels in NMOSD patients. (C) No 
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correlation between CSF sCD40L levels and CSF IL-6 levels in MS patients. (D) Positive 
correlations between CSF sCD40L levels and CSF IL-6 levels in NMOSD patients. IL-6 = 
interleukin-6; MS = multiple sclerosis; NMOSD = neuromyelitis spectrum disorder; sCD40L = 
soluble CD40 ligand. 



Table 1. Demographic and clinical characteristics, laboratory findings and 
treatment in MS and NMOSD patients 
 MS NMOSD P 
 (n = 29) (n = 29)  
Demographic and clinical features 
Female (%) 
 
23/29 (79.3%) 
 
27/29 (93.1%) 
 
0.25 
Age at CSF sampling (years) 36.0 [13.0] 52.0 [22.5] <0.001* 
Disease duration (months) 49.0 [132.5] 65.0 [169.0] 0.40 
Days from attack to CSF sampling 11.0 [18.5] 11.0 [15.0] 0.59 
EDSS 2.5 [2.0] 6.0 [3.0] <0.001* 
Laboratory findings 
Positive anti- aquaporin-4 antibodies 
 
0/29 (0%) 
 
24/29 (82.8%) 
 
<0.001* 
  CSF cell count (/μL) 11.0 [25.0] 8.0 [14.0] 0.45 
  CSF protein concentration (mg/dl) 
Qalb (/10-3) 
32.0 [10.0] 
44.1 [13.9] 
36.0 [28.0] 
60.8 [53.3] 
0.18 
<0.001* 
IgG index 
Positive oligoclonal IgG bands 
0.73 [0.40] 
16/27 (59.3%) 
0.63 [0.22] 
7/26 (26.9%) 
0.069 
0.027* 
Platelet count (103/μL) 257 [88] 255 [110] 0.74 
Treatments 
    Any immunomodulating treatment 
Continuous oral prednisolone 
Azathioprine 
    Interferon-β 
    Fingolimod 
 
2/29 (6.9%) 
0/29 (0%) 
0/29 (0%) 
2/29 (6.9%) 
0/29 (0%) 
 
15/29 (51.7%) 
14/29 (48.3%) 
1/29 (3.4%) 
1/29 (3.4%) 
0/29 (0%) 
 
<0.001* 
<0.001* 
1.0 
0.49 
- 
Data are presented as median [interquartile range] or number (%). 
*P < 0.05. 
CSF: Cerebrospinal fluid; EDSS: Kurtzke’s Expanded Disability Status Scale; 
MS: multiple sclerosis; NMOSD: neuromyelitis optica spectrum disorder. 
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Table 2. Correlation between sCD40L and clinical and laboratory findings in patients with 
MS. 
 
Kendall tau-b 
Serum sCD40L 
P 
Kendall tau-b 
CSF sCD40L 
P 
EDSS 
CSF cell count (/μL) 
CSF protein concentration (mg/dl) 
Qalb (/10-3) 
-0.004 
0.084 
0.21 
0.29 
0.98 
0.58 
0.17 
0.044* 
-0.026 
0.085 
-0.009 
-0.054 
0.87 
0.59 
0.96 
0.72 
IgG index -0.062 0.96 -0.008 0.96 
Serum sCD40L 1.0 NA -0.067 0.62 
CSF sCD40L -0.067 0.62 1.0 NA 
*P < 0.05. CSF: Cerebrospinal fluid; EDSS: Kurtzke’s Expanded Disability Status Scale; 
sCD40L; soluble CD40 ligand; MS: multiple sclerosis. 
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Table 3. Correlation between sCD40L and clinical and laboratory findings in patients with 
NMOSD. 
 
Kendall tau-b 
Serum sCD40L 
P 
Kendall tau-b 
CSF sCD40L 
P 
EDSS 
CSF cell count (/μL) 
CSF protein concentration (mg/dl) 
Qalb (/10-3) 
-0.034 
-0.13 
0.046 
0.022 
0.81 
0.36 
0.74 
0.89 
0.23 
0.30 
0.34 
0.28 
0.10 
0.038* 
0.018* 
0.056 
IgG index -0.062 0.96 0.28 0.056 
Serum sCD40L 1.0 NA 0.12 0.38 
CSF sCD40L 0.12 0.38 1.0 NA 
*P < 0.05. CSF: Cerebrospinal fluid; EDSS: Kurtzke’s Expanded Disability Status Scale; 
sCD40L; soluble CD40 ligand; NMOSD; neuromyelitis optica spectrum disorder. 
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